InvestorsHub Logo
Followers 4
Posts 123
Boards Moderated 0
Alias Born 12/13/2008

Re: kraziman09 post# 6

Thursday, 08/08/2013 10:14:02 AM

Thursday, August 08, 2013 10:14:02 AM

Post# of 16
Don`t know what's going wrong.

I bought some in Germany`FRA

Yesterday`s news:

Epigenomics AG Announces H1 2013 and Q2 2013 Financial Results and Reports on Operational Highlights

07.08.2013

Berlin, Germany, and U.S.A. - Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results for the first half and second quarter of 2013 ending June 30.

Revenue in Q2 2013 increased by 120% to EUR 343 thousand compared to Q2 2012
Operating costs decreased by 44% to EUR 2,098 thousand over Q2 2012
EBIT in Q2 improved by 53% to EUR -1,607 thousand compared to Q2 2012
Net cash flow in H1 2013 positive due to successful capital increase in January
Level 1 ADR program established


www.epigenomics.com/en/news-investors/news-media/press-releases/latest-news/article/epigenomics-ag-gibt-finanzergebnisse-des-ersten-halbjahres-und-zweiten-quartals-2013-bekannt-und-ber.html

jupp